Clinical Trials Logo

Recurrent WHO Grade III Glioma clinical trials

View clinical trials related to Recurrent WHO Grade III Glioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05139056 Recruiting - Clinical trials for Recurrent Glioblastoma

Multiple Doses of Neural Stem Cell Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Start date: May 2, 2023
Phase: Phase 1
Study type: Interventional

This phase I trial studies the effect of multiple doses of NSC-CRAd-S-pk7 in treating patients with high-grade gliomas that have come back (recurrent). NSC-CRAd-S-pk7 consists of neural stem cells that carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.

NCT ID: NCT05009992 Recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Start date: October 20, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating patients with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for patients with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phase II trial assesses different combinations of these drugs for the treatment of DMGs.

NCT ID: NCT04540107 Recruiting - Clinical trials for WHO Grade III Glioma

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Start date: January 11, 2017
Phase: Phase 1
Study type: Interventional

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.

NCT ID: NCT04214392 Recruiting - Clinical trials for Recurrent Glioblastoma

Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma

Start date: February 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of chimeric antigen receptor (CAR) T cells with a chlorotoxin tumor-targeting domain in treating patients with MPP2+ glioblastoma that has come back (recurrent) or that is growing, spreading, or getting worse (progressive). Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT03749187 Recruiting - Glioblastoma Clinical Trials

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

PNOC017
Start date: April 3, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.